TY - JOUR
T1 - 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
AU - Relkin, Norman R.
AU - Szabo, Paul
AU - Adamiak, Basia
AU - Burgut, Tuna
AU - Monthe, Carmen
AU - Lent, Richard W.
AU - Younkin, Steven
AU - Younkin, Linda
AU - Schiff, Richard
AU - Weksler, Marc E.
N1 - Funding Information:
The research studies reported were supported, in part, by the General Clinical Research Center at the Weill Medical College of Cornell University, NIH/NCRR Grant M01 RR00047. Additional financial support was provided by Baxter Bioscience Corporation, by NIH grant AG-021033, and the Stern Family Fund (MW) as well as the gifts from the Hoyt, Chen, and Koplow families (NR). IVIg for the study was also supplied by Baxter Bioscience Corporation.
PY - 2009/11
Y1 - 2009/11
N2 - Intravenous immunoglobulin (IVIg) has been proposed as a potential agent for Alzheimer's disease (AD) immunotherapy because it contains antibodies against beta-amyloid (Aβ). We carried out an open label dose-ranging study in 8 mild AD patients in which IVIg was added to approved AD therapies for 6 months, discontinued, and then resumed for another 9 months. Infusions were generally well-tolerated. Anti-Aβ antibodies in the serum from AD patients increased in proportion to IVIg dose and had a shorter half-life than anti-hepatitis antibodies and total IgG. Plasma Aβ levels increased transiently after each infusion. Cerebrospinal fluid Aβ decreased significantly at 6 months, returned to baseline after washout and decreased again after IVIg was re-administered for an additional 9 months. Mini-mental state scores increased an average of 2.5 points after 6 months, returned to baseline during washout and remained stable during subsequent IVIg treatment. Our findings confirm and extend those obtained by Dodel et al. [Dodel, R.C., Du, Y., Depboylu, C., Hampel, H., Frolich, L., Haag, A., Hemmeter, U., Paulsen, S., Teipel, S.J., Brettschneider, S., Spottke, A., Nolker, C., Moller, H.J., Wei, X., Farlow, M., Sommer, N., Oertel, W.H., 2004. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75, 1472-1474] from a 6-month trial of IVIg in 5 AD patients and justify further studies of IVIg for treatment of AD.
AB - Intravenous immunoglobulin (IVIg) has been proposed as a potential agent for Alzheimer's disease (AD) immunotherapy because it contains antibodies against beta-amyloid (Aβ). We carried out an open label dose-ranging study in 8 mild AD patients in which IVIg was added to approved AD therapies for 6 months, discontinued, and then resumed for another 9 months. Infusions were generally well-tolerated. Anti-Aβ antibodies in the serum from AD patients increased in proportion to IVIg dose and had a shorter half-life than anti-hepatitis antibodies and total IgG. Plasma Aβ levels increased transiently after each infusion. Cerebrospinal fluid Aβ decreased significantly at 6 months, returned to baseline after washout and decreased again after IVIg was re-administered for an additional 9 months. Mini-mental state scores increased an average of 2.5 points after 6 months, returned to baseline during washout and remained stable during subsequent IVIg treatment. Our findings confirm and extend those obtained by Dodel et al. [Dodel, R.C., Du, Y., Depboylu, C., Hampel, H., Frolich, L., Haag, A., Hemmeter, U., Paulsen, S., Teipel, S.J., Brettschneider, S., Spottke, A., Nolker, C., Moller, H.J., Wei, X., Farlow, M., Sommer, N., Oertel, W.H., 2004. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75, 1472-1474] from a 6-month trial of IVIg in 5 AD patients and justify further studies of IVIg for treatment of AD.
KW - Alzheimer's disease
KW - Amyloid beta peptides
KW - Immunotherapy
KW - Intravenous immunoglobulin
UR - http://www.scopus.com/inward/record.url?scp=70049083865&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70049083865&partnerID=8YFLogxK
U2 - 10.1016/j.neurobiolaging.2007.12.021
DO - 10.1016/j.neurobiolaging.2007.12.021
M3 - Article
C2 - 18294736
AN - SCOPUS:70049083865
SN - 0197-4580
VL - 30
SP - 1728
EP - 1736
JO - Neurobiology of aging
JF - Neurobiology of aging
IS - 11
ER -